[{"id":"4df095d5-85b3-400e-86eb-3ef2e22e4f1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03513484","created_at":"2021-01-18T17:17:32.073Z","updated_at":"2024-07-02T16:35:25.364Z","phase":"Phase 1","brief_title":"Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03513484","lead_sponsor":"Northwestern University","biomarkers":" FLT3 • KMT2A • CD34 • HOXA9 • FGF2","pipe":" | ","alterations":" HOXA9 overexpression","tags":["FLT3 • KMT2A • CD34 • HOXA9 • FGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HOXA9 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-12-22"}]